
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION
FOR IMMEDIATE RELEASE
Financial Results for the first quarter ended
"I am pleased to report a positive start to 2025. In Q1 2025, we delivered a 41% increase in average daily titled production year-over-year and total processed volumes increased by 68% to 24,009 boepd. These increases were driven by the ramp-up of
We achieved a key milestone with the approval of the phased full-field development plan for the Stepnoy Leopard fields, targeting production start-up between late 2026 and early 2027. The extension of our processing agreement with Ural O&G through to
Q1 2025 Highlights:
Financial
· Revenue of
· A 2.8% increase in EBITDA1:
· A 39.5% reduction in operating expenses per barrel of processed volumes:
· Net operating cashflow in Q1 2025 was affected by the deferment of crude oil sales, as described above. This, together with capital expenditures, resulted in a
· Unrestricted cash balance of
· Net debt2 of
Operational
· Production and sales
· A 41% increase in average daily titled production volumes (i.e. final products processed and owned by Nostrum) to 16,830 boepd in Q1 2025 (11,943 boepd in Q1 2024). A 68% increase in total processed volumes (including third party condensate tolling volumes) to 24,009 boepd in Q1 2025 (14,319 boepd in Q1 2024). These increases in titled production and processed volumes were mainly due to:
· Ramp up of the production by Ural O&G, which contributed to increase in Nostrum's titled production and processed volumes.
· Production from well No.301 which was completed and put into production in May 2024.
· The titled production volume split was as follows:
Products |
Q1 2025 volumes (boepd) |
Q1 2024 volumes (boepd) |
Y-on-Y change (%) |
|
Q1 2025 product mix (%) |
Q1 2024 product mix (%) |
Crude Oil |
2,650 |
2,382 |
11.3% |
|
15.7% |
19.9% |
Stabilised Condensate* |
1,678 |
1,934 |
(13.2)% |
|
10.0% |
16.2% |
LPG ( |
3,077 |
1,858 |
65.6% |
|
18.3% |
15.6% |
|
9,425 |
5,769 |
63.4% |
|
56.0% |
48.3% |
Total |
16,830 |
11,943 |
40.9% |
|
100.0% |
100.0% |
*Stabilized condensate volumes exclude Ural O&G processed volumes for which Nostrum receives a tolling fee
· A 47% increase in average daily sales volumes to 14,128 boepd for Q1 2025 (Q1 2024: 10,022 boepd). The difference between titled production and sales volumes is primarily due to the internal consumption of dry gas produced and timing of product deliveries, which leads to inventory increases or decreases at period end.
· Chinarevskoye drilling programme
The Company is planning a limited-scale drilling campaign in the second half of 2025, focused on high-value subsurface opportunities, which will also ensure full compliance with its license commitments.
· Stepnoy Leopard Fields
The Company achieved another significant milestone in unlocking the commercial viability and potential of this upstream acquisition. As announced on
· Processing of Ural O&G products
Throughout Q1 2025, the Company continued processing raw gas and condensate volumes from Ural O&G, significantly contributing to the increases in titled production and processed volumes.
As announced on
HSE and ESG
· Zero fatalities among employees and contractors during operations for Q1 2025 (Q1 2024: zero).
· One Total Recordable Incidents (incidents per million man-hours) for Q1 2025 (Q1 2024: zero).
· Zero Lost Time Injury (incidents per million man-hours) for Q1 2025 (Q1 2024: zero)
· 1,109 tonnes of air emissions emitted in Q1 2025 against 5,188 tonnes permitted for FY 2025 under the Kazakhstan Environmental Code.
· Safety of all staff and contractors, along with a commitment to sustainable operations, remains the Group's priority.
The next investor and analyst call will take place in August 2025 as part of Nostrum's H1 2025 results publication.
The Company's Q1 2025 Interim condensed consolidated financial statements are available to download on Nostrum's website:
Download: Q1 2025 Interim condensed consolidated financial statements
Notes to press release
1 EBITDA is a non-IFRS measure and is defined as profit / loss before tax and depreciation, depletion and amortisation, share-based compensation, foreign exchange gains / losses, finance costs, interest income, other income, other expenses, and one-off items.
2 Net debt is defined as total debt (notes payable and accumulated interest) less cash and cash equivalents and DSRA.
LEI: 2138007VWEP4MM3J8B29
Further information
For further information please visit www.nostrumoilandgas.com
Further enquiries
Chief Financial Officer
Galyna Kulachek
+ 44 (0) 207 457 2020
About
Forward-Looking Statements
Some of the statements in this document are forward-looking. Forward-looking statements include statements regarding the intent, belief and current expectations of the Company or its officers with respect to various matters. When used in this document, the words "expects", "believes", "anticipates", "plans", "may", "will", "should" and similar expressions, and the negatives thereof, are intended to identify forward-looking statements. Such statements are not promises nor guarantees and are subject to risks and uncertainties that could cause actual outcomes to differ materially from those suggested by any such statements.
No part of this announcement constitutes, or shall be taken to constitute, an invitation or inducement to invest in the Company or any other entity, and shareholders of the Company are cautioned not to place undue reliance on the forward-looking statements. Save as required by the relevant listing rules and applicable law, the Company does not undertake to update or change any forward-looking statements to reflect events occurring after the date of this announcement.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the